Author

Shelli M. Morris

Seattle Children's Research InstituteORCID 0000-0001-6397-0117Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Emily J. GirardiD· 3 shared James M. OlsoniD· 2 shared Kenneth Brasel· 2 shared Alison M. Williams· 1 shared Andrew BondociD· 1 shared Annie HuangiD· 1 shared Augusto Faria AndradeiD· 1 shared Banlanjo Abdulaziz UmaruiD· 1 shared

Activity by Year

2023-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 32 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Emily J. GirardORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 31, 2026

Intratumoral B7H3:CD3 Bispecific T-cell Engager Drives Localized T-cell Accumulation in Canine Sarcoma Patients

Yusuke Suita, Lisa S. Ang, Kenneth Brasel…·James M. Olson

This study evaluates an intratumoral B7H3:CD3 TCE in canine sarcoma patients, showing localized T-cell accumulation without systemic toxicity.

DOI 10.64898/2026.05.27.728355

non-human primateexperimental assay

𝕏 PostBluesky

ImmunologybioRxivPreprintMay 14, 2025

Efficacy of DNA Methyltransferase Inhibitor Immune Priming Therapy in Combination with PD-1 Inhibitors to Treat High-Risk Pediatric Brain Tumors

Deepak Kumar Mishra, Shelli M. Morris, Dean Popovski…·Rachid Drissi

This study investigates the combination of DNA methyltransferase inhibitor decitabine and PD-1 inhibitor in high-risk pediatric brain tumor models, finding improved survival in some subtypes.

DOI 10.1101/2025.05.14.654106

mouseDNA methylation

𝕏 PostBluesky

Cancer BiologybioRxivPreprintAug 30, 2023

Chromatin Profiling of CBFA2T3-GLIS2 AMLs Identifies Key Transcription Factor Dependencies and BRG1 Inhibition as a Novel Therapeutic Strategy

Samantha Kaonis, Jenny L. Smith, Neerja Katiyar…·Jay F. Sarthy

This study identifies BRG1 inhibition as a therapeutic strategy for CBFA2T3-GLIS2 AML by analyzing chromatin profiles and CRISPR dependencies.

6 citations

𝕏 PostBluesky